Who wrote this article?

Aakash Agarwal, Capitalmind's research team.

Aurobindo Pharma's Arrow Generiques To Acquire Select Assets From Teva

25 Nov 2016Aakash Agarwal1 min read

Quick Facts

What is "Aurobindo Pharma's Arrow Generiques To Acquire Select Assets From Teva" about?
What category is this article in?: Stocks
Who wrote this article?: Aakash Agarwal, Capitalmind's research team.
When was this article published?: Published 25 November 2016.
How long does this article take to read?: 1 min read
What topics does this article cover?: AUROPHARMA, Pharmaceuticals

Arrow Generiques - French subsidiary of Hyderabad based Aurobindo Pharma focused on selling generic on the retail and hospital market having around 800 generic pharmaceuticals, and several brand medications has announced the signing of an agreement with Teva Pharmaceuticals subject to approval of the European Commission.

As part of this agreement, Arrow will acquire select commercial products along will the right, title and interest in products Calcium and Calcium Vitamin D3, including the use of the OROCAL trademark. Teva had acquired the product from Theramex in 2010.

Once acquired, Arrow Generiques will integrate these products with its existing commercial operations in France, and focus on maximizing their potential. This deal will boost the position of Arrow Generiques and open new opportunities for the future.